Comparison Overview

Cipla

VS

Takeda

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2026-01-24
Between 750 and 799

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 50,326
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Takeda

Tokyo, JP
Last Update: 2026-01-18
Between 800 and 849

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 37,228
Subsidiaries: 6
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/takeda-pharmaceuticals.jpeg
Takeda
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Cipla
100%
Compliance Rate
0/4 Standards Verified
Takeda
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Takeda in 2026.

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Incident History — Takeda (X = Date, Y = Severity)

Takeda cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

https://images.rankiteo.com/companyimages/takeda-pharmaceuticals.jpeg
Takeda
Incidents

Date Detected: 1/2024
Type:Breach
Attack Vector: Credential Stuffing
Blog: Blog

FAQ

Takeda company demonstrates a stronger AI Cybersecurity Score compared to Cipla company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Takeda company has historically faced a number of disclosed cyber incidents, whereas Cipla company has not reported any.

In the current year, Takeda company and Cipla company have not reported any cyber incidents.

Neither Takeda company nor Cipla company has reported experiencing a ransomware attack publicly.

Takeda company has disclosed at least one data breach, while Cipla company has not reported such incidents publicly.

Neither Takeda company nor Cipla company has reported experiencing targeted cyberattacks publicly.

Neither Cipla company nor Takeda company has reported experiencing or disclosing vulnerabilities publicly.

Neither Cipla nor Takeda holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to Takeda company.

Cipla company employs more people globally than Takeda company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Cipla nor Takeda holds SOC 2 Type 1 certification.

Neither Cipla nor Takeda holds SOC 2 Type 2 certification.

Neither Cipla nor Takeda holds ISO 27001 certification.

Neither Cipla nor Takeda holds PCI DSS certification.

Neither Cipla nor Takeda holds HIPAA certification.

Neither Cipla nor Takeda holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Improper validation of specified type of input in M365 Copilot allows an unauthorized attacker to disclose information over a network.

Risk Information
cvss3
Base: 9.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N
Description

Improper access control in Azure Front Door (AFD) allows an unauthorized attacker to elevate privileges over a network.

Risk Information
cvss3
Base: 9.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Description

Azure Entra ID Elevation of Privilege Vulnerability

Risk Information
cvss3
Base: 9.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:L/A:N
Description

Moonraker is a Python web server providing API access to Klipper 3D printing firmware. In versions 0.9.3 and below, instances configured with the "ldap" component enabled are vulnerable to LDAP search filter injection techniques via the login endpoint. The 401 error response message can be used to determine whether or not a search was successful, allowing for brute force methods to discover LDAP entries on the server such as user IDs and user attributes. This issue has been fixed in version 0.10.0.

Risk Information
cvss4
Base: 2.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:U/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Runtipi is a Docker-based, personal homeserver orchestrator that facilitates multiple services on a single server. Versions 3.7.0 and above allow an authenticated user to execute arbitrary system commands on the host server by injecting shell metacharacters into backup filenames. The BackupManager fails to sanitize the filenames of uploaded backups. The system persists user-uploaded files directly to the host filesystem using the raw originalname provided in the request. This allows an attacker to stage a file containing shell metacharacters (e.g., $(id).tar.gz) at a predictable path, which is later referenced during the restore process. The successful storage of the file is what allows the subsequent restore command to reference and execute it. This issue has been fixed in version 4.7.0.

Risk Information
cvss3
Base: 8.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:H/A:H